"Eating too much or too little could actually be a genetic problem, rather than an insulin issue," said Toshio Nakaki, M.D., Ph.D., a researcher in the Department of Pharmacology, Teikyo University School of Medicine, in Tokyo, Japan. "Drugs targeting the GTRAP3-18 gene could be therapeutic for obesity or appetite-related disorders."
‘Drugs targeting GTRAP3-18 gene could help treat obesity and appetite-related disorders.’
Nakaki and colleagues analyzed a group of mice defective in the GTRAP3-18 gene. The GTRAP3-18-deficient mice were lean as compared with wild type mice. The leanness was due to neither increased locomotive activity nor basal metabolism, but rather a dysregulation of feeding behavior, or hypophagia. The GTRAP3-18-deficient mice also displayed hypoglycemia.
"This revealing investigation opens a new window on what is likely to be a key regulatory loop in the food intake-weight control axis, with considerable therapeutic potential," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal